Contrive Datum Insights has published "Drug Discovery Market Size, Share & Industry Analysis, By Workflow (Target Identification & Screening, Target Validation & Functional Informatics, Lead Identification & Candidate Optimization, Preclinical Development, Other Associated Workflow), Therapeutics area (Oncology, Central Nervous System, Cardiovascular, Anti-infective, Immunomodulation, Endocrine, Gastrointestinal, Hematology, Respiratory System, Genitourinary System, Dermatology, Ophthalmology, Pain and Anesthesia), Drug type (Small Molecules, Large Molecules (Biopharmaceuticals)), Type (Chemistry Services, Biology Services), End-user (Pharmaceutical & Biotechnology companies, Academic Institutes, Others), and Regional Forecast, 2026-2034". The study sizes the global drug discovery market at USD 74.5 billion in 2025 and projects growth from USD 81.5 billion in 2026 to USD 164.78 billion by 2034, a compound annual growth rate of 9.2% across the forecast period.
Drug discovery covers the research services and platforms used to identify, validate and optimize new therapeutic candidates before they enter formal preclinical testing, spanning target identification, hit-to-lead chemistry, biological screening and early candidate characterization. Work is carried out both in-house by pharmaceutical and biotechnology research teams and through contract research organizations that provide chemistry, biology and informatics capacity on an outsourced basis. Buyers range from large pharmaceutical companies running internal pipelines to smaller biotechnology firms and academic research groups that rely on external providers for specialized screening and validation capabilities.
Rising biologics and cell and gene therapy pipelines requiring specialized discovery services
Rising biologics and cell and gene therapy pipelines requiring specialized discovery services is the largest single contributor to the market's growth over the forecast period, and the study rates its impact high. Against a market growing at 9.2% a year, the workflow lines exposed to it move fastest: Target Identification & Screening compounds at 10.76%, taking its share of revenue from 22% to 25% and its value from USD 16.39 billion to USD 41.2 billion.
On the upside, the study's bull case assumes bull case assumes biologics and cell and gene therapy pipeline growth and Asia Pacific outsourcing capacity both expand faster than the base case, pulling discovery spending forward across therapeutic areas, which would take 2034 revenue to USD 181.26 billion rather than the USD 164.78 billion base case.
However, bear case assumes pharmaceutical R&D budget rationalization and slower biologics pipeline progression reduce discovery spending growth relative to the base case across most therapeutic areas and regions, which would hold 2034 revenue to USD 148.3 billion. Lead Identification & Candidate Optimization, which carries 32% of 2025 revenue, already grows at only 8.82% against the market's 9.2%, so the largest part of the base is also its slowest.
Key Players Compete on Lead Identification & Candidate Optimization Volume and Target Identification & Screening Growth
Competition in the global drug discovery market runs along the workflow axis rather than the regional one. Lead Identification & Candidate Optimization holds 32% of 2025 revenue at USD 23.84 billion and remains the largest line through 2034 at 31%, making it the position hardest for a challenger to take. Target Identification & Screening, growing at 10.76%, is where share actually changes hands. A supplier established in one is not thereby established in the other, which is what sustains a field of this size in a market of USD 74.5 billion.
Further Report Findings
| Segment | Led 2025 by | Share & value | Fastest-growing |
|---|---|---|---|
| Workflow | Lead Identification & Candidate Optimization | 32% · USD 23.84 billion | — |
| Therapeutics area | Oncology | 26% · USD 19.37 billion | Immunomodulation 10.5% |
| Drug type | Small Molecules | 58% · USD 43.21 billion | Large Molecules (Biopharmaceuticals) 10.84% |
| Type | Chemistry Services | 55% · USD 40.98 billion | Biology Services 10.51% |
| End-user | Pharmaceutical & Biotechnology companies | 68% · USD 50.66 billion | — |
- Based on regional analysis, North America led the global drug discovery market in 2025 with 42% of global revenue at USD 31.29 billion, reaching USD 62.62 billion by 2034.
- Asia Pacific takes a rising share of global revenue over the forecast period, from 27% in 2025 to 33% in 2034, with revenue growing from USD 20.12 billion to USD 54.38 billion.
- Middle East and Africa remains the smallest region throughout, at 3% of 2025 revenue and 3% by 2034.
- Target Identification & Screening is projected to grow at 10.76% over the forecast period, the fastest of any workflow line.
- The United States is the largest single country market at USD 26.6 billion in 2025, 35.7% of global revenue.
The report segments the market across five axes; by workflow, and by therapeutics area, drug type, type and end-user; with revenue and a growth rate for every line in every year from 2020 to 2034, alongside bear, base and bull scenarios for the headline total at USD 148.3 billion and USD 181.26 billion by 2034. It covers all five regions with country-level breakdowns, the competitive landscape, and the research methodology behind every estimate. Delivered as a PDF; a free sample is available on request.